Ozempic Is Huge. Here’s Who’s Jumping into Telehealth to Sell It.

The rising popularity of glucagon-like peptide agonists has led to a gold rush of companies offering telehealth weight-loss services. GLP-1s, a class of medications that can help with weight loss and diabetes, have become big business in a short period of time. Drugmaker Novo Nordisk, which manufactures injectable GLP-1 agonist medications Ozempic and Wegovy, booked more than $12 billion in revenue in 2023’s first nine months from those two drugs alone. Here’s a rundown on who’s entered the GLP-1 telehealth market since 2022.

Read the full article: Ozempic Is Huge. Here’s Who’s Jumping into Telehealth to Sell It. //

Source: https://www.modernhealthcare.com/digital-health/ozempic-telehealth-mayo-clinic-noom-teladoc-weightwatchers

Leave a Comment

Your email address will not be published.

Scroll to Top